Citations

Mayo Clinic

Showing 10 of 108572 citations.

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001
Deschler-Baier, Barbara , Han, Yimei , Kiiskinen, Urpo , Jen, Min‐Hua , Barker, Scott , Szymczak, Sylwia, Gilligan, Adrienne M., Braud, Filippo de , Morris, John C., Worden, Francis P. , Szymczak, Sylwia

Cancers | December 27, 2023 | Volume: 16 | Issue: 1 | Pages: 140

10.3390/cancers16010140 | PMID 38201566 Get It

Selpercatinib is indicated for locally advanced/metastatic RET-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness data comparing selpercatinib with other first-line treatments in RET-activated non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and thyroid cancer (TC). This study analyzed patient data from LIBRETTO-001 and compared the outcomes (time to treatment discontinuation {TTD}, time to next treatment or death {TTNT-D}, time to progression {TTP}, and the objective response rate {ORR}) of first-line selpercatinib (selpercatinib arm) use with the outcomes of first-line standard therapies in patients who then received selpercatinib in later lines of treatment (comparator arm). Overall, the first-line selpercatinib arm had a longer TTD, TTNT-D, and TTP versus the first-line comparator arm. The hazard ratios (HRs) for TTD were 0.29 (NSCLC), 0.15 (MTC), 0.08 (TC); for TTNT-D, the HRs were 0.48 (NSCLC), 0.11 (MTC), 0.09 (TC); and for TTP, the HRs were 0.54 (NSCLC), 0.15 (MTC), and 0.12 (TC). The ORR was higher for first-line selpercatinib versus the first-line comparator (NSCLC: 85.3% vs. 39.7%; MTC: 82.6% vs. 15.2%; and TC: 81.8% vs. 31.8%). First-line selpercatinib use is associated with improved outcomes compared to first-line comparator therapies for patients with advanced/metastatic RET-activated cancers.
Sex Makes a Difference in Aging: Biology and Beyond
Anderson, Rozalyn M. , Yousefzadeh, Matthew J. , Ghosh, Bhaswati, Anderson, Rozalyn M , Rogina, Blanka , LeBrasseur, Nathan K.

Public Policy & Aging Report | December 27, 2023 | Volume: 33 | Issue: 4 | Pages: 111-112

10.1093/ppar/prad028 Get It

Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis
Deng, Jiawen , Moskalyk, Myron , Zuo, Qi , Garcia, Michael Cristian , Abbas, Umaima , Ramaraju, Harikrishnaa Ba , Rayner, Daniel , Park, Ye‐Jean , Heybati, Kiyan , Zhou, Fangwen , Lohit, Simran , Zuo, Qi Kang , Garcia, Cristian , Deng, J , Zhou, F

Reviews in Medical Virology | December 27, 2023 | Volume: 34 | Issue: 1 | Pages: No page available

10.1002/rmv.2501 | PMID 38148036 Get It

AbstractThis systematic review and meta‐analysis of randomised controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of fluvoxamine for the outpatient management of COVID‐19. We conducted this review in accordance with the PRISMA 2020 guidelines. Literature searches were conducted in MEDLINE, EMBASE, International Pharmaceutical Abstracts, CINAHL, Web of Science, and CENTRAL up to 14 September 2023. Outcomes included incidence of hospitalisation, healthcare utilization (emergency room visits and/or hospitalisation), mortality, supplemental oxygen and mechanical ventilation requirements, serious adverse events (SAEs) and non‐adherence. Fluvoxamine 100 mg twice a day was associated with reductions in the risk of hospitalisation (risk ratio [RR] 0.75, 95% confidence interval [CI] 0.58–0.97; I 2 = 0%) and reductions in the risk of healthcare utilization (RR 0.68, 95% CI 0.53–0.86; I 2 = 0%). While no increased SAEs were observed, fluvoxamine 100 mg twice a day was associated with higher treatment non‐adherence compared to placebo (RR 1.61, 95% CI 1.22–2.14; I 2 = 53%). In subgroup analyses, fluvoxamine reduced healthcare utilization in outpatients with BMI ≥30 kg/m2, but not in those with lower BMIs. While fluvoxamine offers potential benefits in reducing healthcare utilization, its efficacy may be most pronounced in high‐risk patient populations. The observed non‐adherence rates highlight the need for better patient education and counselling. Future investigations should reassess trial endpoints to include outcomes relating to post‐COVID sequelaes. Registration: This review was prospectively registered on PROSPERO (CRD42023463829).
Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale
Li, Suzanne C. , Rabinovich, C. Egla, Becker, Mara L. , Ferguson, Polly J. , Dedeoğlu, Fatma , Hong, Sandy , Laxer, Ronald M. , Stewart, Katie, Ibarra, Maria, Mason, Thomas G. , Higgins, Gloria C., Li, Xiaohu , Fuhlbrigge, Robert C. , Investigators, for the CARRA Registry, Dedeoglu, Fatma , Mason, Thomas, Lozy, Tara , Torok, Kathryn S. , Sivaraman, Vidya , Mason, Thomas, Pope, Elena , Investigators, for the CARRA Registry

Arthritis Care & Research | December 27, 2023 | Volume: 76 | Issue: 5 | Pages: 616-626

10.1002/acr.25281 | PMID 38148547 Get It

ObjectiveJuvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcomes, including contractures, hemiatrophy, uveitis, and seizures. Despite improvements in treatment, >25% of patients with jLS have functional impairment. To improve patient evaluation, our workgroup developed the Localized scleroderma Total Severity Scale (LoTSS), an overall disease severity measure.MethodsLoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multicriteria decision analysis. Feasibility was assessed in larger Childhood Arthritis and Rheumatology Research Alliance groups. Construct validity with physician assessment and inter‐rater reliability was assessed using case vignettes. Additional evaluation was performed in a prospective patient cohort initiating treatment.ResultsLoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by a strong positive correlation with the Physician Global Assessment (PGA) of severity and damage and weak positive correlation with PGA‐Activity, as expected. LoTSS was responsive, with a small effect size identified. Moderate‐to‐excellent inter‐rater reliability was demonstrated. LoTSS was able to discriminate between patient subsets, with higher scores identified in those with greater disease burden and functional limitation.ConclusionWe developed a new LS measure for assessing cutaneous and extracutaneous severity and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the major extracutaneous manifestations in LS. Our findings suggest LoTSS could aid assessment and management of patients and facilitate outcome evaluation in treatment studies.image
How Participatory Health Informatics Catalyzes One Digital Health
Miron‐Shatz, Talya , Petersen, Carolyn , Petersen, Carolyn , Denecke, Kerstin , Rivera-Romero, Octavio , Merolli, Mark , Gabarrón, Elia

Yearbook of Medical Informatics | December 26, 2023 | Volume: 32 | Issue: 01 | Pages: 048-054

10.1055/s-0043-1768727 | PMID 38147849 Get It

Objective: To identify links between Participatory Health Informatics (PHI) and the One Digital Health framework (ODH) and to show how PHI could be used as a catalyst or contributor to ODH. Methods: We have analyzed the addressed topics within the ODH framework in previous IMIA Yearbook contributions from our working group during the last 10 years. We have matched main themes with the ODH's framework three perspectives (individual health and wellbeing, population and society, and ecosystem). Results: PHI catalysts ODH individual health and wellbeing perspective by providing a more comprehensive view on human health, attitudes, and relations between human health and animal health. Integration of specific behavior change techniques or gamification strategies in digital solutions are effective to change behaviors which address the P5 paradigm. PHI supports the population and society perspective through the engagement of the various stakeholders in healthcare. At the same time, PHI might increase a risk for health inequities due to technologies inaccessible to all equally and challenges associated with this. PHI is a catalyst for the ecosystem perspective by contributing data into the digital health data ecosystem allowing for analysis of interrelations between the various data which in turn might provide links among all components of the healthcare ecosystem. Conclusion: Our results suggest that PHI can and will involve topics relating to ODH. As the ODH concept crystalizes and becomes increasingly influential, its themes will permeate and become embedded in PHI even more. We look forward to these developments and co-evolution of the two frameworks.
Spontaneous Extensive Type A Aortic Dissection in an Older Female with No Risk Factors: A Rare Clinical Presentation
Lathiya, Maulik , Cullinan, Susan M. , Lathiya, Maulik K , Cullinan, Susan M

Case Reports in Emergency Medicine | December 26, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-5

10.1155/2023/4950510 | PMID 38170040 Get It

Background. Aortic dissection (AD) is a rare but serious medical emergency where the aorta’s inner layer tears. Females are less likely to develop it than males, and AD cases with unusual symptoms can be hard to diagnose. Diagnosing AD can be further complicated as its symptoms and electrocardiogram (ECG) changes can mimic acute coronary syndrome, and it is challenging to distinguish it without risk factors. Case Report. This case report describes a 60-year-old female patient who presented with unusual symptoms, including pain in her chest, neck, left arm, and lower extremities. An electrocardiogram (ECG) revealed ST elevation in leads aVR and V1, as well as severe ST depression and T wave inversion in the inferior and lateral leads, which can mimic acute coronary syndrome. Despite initial treatment with nitroglycerin, the patient’s pain worsened, and a CT angiography revealed type A aortic dissection extending from the aortic root to the right external iliac artery. Immediate surgery was recommended, which significantly improved the patient’s condition. Conclusions. Be aware of aortic dissection and its symptoms, even if there are no risk factors or recognizable symptoms. Consider aortic dissection as a potential diagnosis if ECG changes are present. Ongoing education can help decrease mortality and increase awareness.
Middle meningeal artery embolization for chronic subdural hematoma: A single-center experience and predictive modeling of outcomes
Cohen-Cohen, Salomón , Jabal, Mohamed Sobhi , Rinaldo, Lorenzo , Cloft, Harry J. , Brinjikji, Waleed , Cloft, Harry, Savastano, Luis , Lanzino, Giuseppe

The Neuroradiology Journal | December 26, 2023 | Volume: 37 | Issue: 2 | Pages: 192-198

10.1177/19714009231224431 | PMID 38147825 Get It

Background Remarkable interest is rising around middle meningeal artery embolization (MMAE) as an emerging alternative therapy for chronic subdural hematoma (cSDH). The study aims to highlight a large center experience and the variables associated with treatment failure and build experimental machine learning (ML) models for outcome prediction. Material and Methods A 2-year experience in MMAE for managing patients with chronic subdural hematoma was analyzed. Descriptive statistical analysis was conducted using imaging and clinical features of the patients and cSDH, which were subsequently used to build predictive models for the procedure outcome. The modeling evaluation metrics were the area under the ROC curve and F1-score. Results A total of 100 cSDH of 76 patients who underwent MMAE were included with an average follow-up of 6 months. The intervention had a per procedure success rate of 92%. Thrombocytopenia had a highly significant association with treatment failure. Two patients suffered a complication related to the procedure. The best performing machine learning models in predicting MMAE failure achieved an ROC-AUC of 70%, and an F1-score of 67%, including all patients with or without surgical intervention prior to embolization, and an ROC-AUC of 82% and an F1-score of 69% when only patients who underwent upfront MMAE were included. Conclusion MMAE is a safe and minimally invasive procedure with great potential in transforming the management of cSDH and reducing the risk of surgical complications in selected patients. An ML approach with larger sample size might help better predict outcomes and highlight important predictors following MMAE in patients with cSDH.
High-Dose Glucocorticoids for Treating Sudden Hearing Loss: Cart before the Horse?
Yin, Jun, Mandrekar, Sumithra J.

NEJM Evidence | December 26, 2023 | Volume: 3 | Issue: 1 | Pages: No page available

10.1056/evide2300296 | PMID 38320518 Get It

Looking Beyond Syndrome-Based Criteria for Autoimmune Encephalitis—The Need for Complementary Neural Antibody–Based Diagnostic Criteria
Irani, Sarosh R. , Irani, Sarosh R , Budhram, Adrian , Flanagan, Eoin P.

JAMA Neurology | December 26, 2023 | Volume: 81 | Issue: 3 | Pages: 227

10.1001/jamaneurol.2023.4894 | PMID 38147324 Get It

This Viewpoint discusses how neural antibody–based diagnostic criteria for autoimmune encephalitis would complement the syndrome-based diagnostic algorithm to improve sensitivity while maintaining high specificity.